Sterling Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Sterling Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-30,273	Closed	-$77K	–	1037
2016 Q4	$77K	Sell	30,273 -385	-1%	-$1.1K	﹤0.01%	944
2016 Q3	$95K	Hold	30,658	–	–	﹤0.01%	890
2016 Q2	$98K	Hold	30,658	–	–	﹤0.01%	906
2016 Q1	$95K	Hold	30,658	–	–	﹤0.01%	888
2015 Q4	$123K	Sell	30,658 -3,888	-11%	-$17.9K	﹤0.01%	956
2015 Q3	$158K	Sell	34,546 -11,100	-24%	-$58.1K	﹤0.01%	932
2015 Q2	$237K	Hold	45,646	–	–	﹤0.01%	829
2015 Q1	$286K	Buy	45,646 +34,886	+324%	+$201K	﹤0.01%	798
2014 Q4	$68K	Sell	10,760 -4,756	-31%	-$29K	﹤0.01%	903
2014 Q3	$94K	Buy	+15,516	New	+$106K	﹤0.01%	883
2014 Q2	–	Sell	-29,667	Closed	-$706K	–	963
2014 Q1	$706K	Buy	+29,667	New	+$430K	0.01%	686
2013 Q3	–	Sell	-23,125	Closed	-$304K	–	727
2013 Q2	$304K	Buy	+23,125	New	+$312K	﹤0.01%	502

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CRC

Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return

Sterling Capital Management's ECYT Position: Q1 2017 in Review

Sterling Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2017, closing a stake of 30,273 shares — an estimated $77K sold.

Sterling Capital Management first reported a position in ECYT in Q2 2013 and held it in 12 quarters. The position peaked at $706K in Q1 2014. 82 funds tracked by Wall St. Rank hold ECYT as of Q1 2017.

Sterling Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
Sterling Capital Management sold 30,273 Endocyte, Inc. Common Stock shares in Q1 2017, an estimated $77K.
Sterling Capital Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
Sterling Capital Management's Endocyte, Inc. Common Stock position peaked at $706K in Q1 2014.
82 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2017.

Based on Sterling Capital Management's 13F filing for Q1 2017, filed 15 May 2017.